iPS Cells & Regenerative Medicine | Technology, Institution & Company Guides

IPS / REGENERATIVE MEDICINE KNOWLEDGE LIBRARY

Technology, Institution
& Company Guides

Select a technology, institution, or company to open its illustrated guide with source-linked explanations.

28 technology guides8 institution profiles25 company profiles

Reprogram, then direct cells towards a specific role

READ THIS FIRST

A Beginner’s Guide to iPS cells and regenerative medicine

The path from making cells to using them safely and usefully. No prior knowledge needed: understand the purpose, mechanism, strengths and limits, then choose a guided route into the detailed articles.

Start with the overview →

Technology Guides

28 illustrated explainers

Autologous and Allogeneic Cell Therapies Biomarkers and Clinical Endpoints Bioprinting and Bioinks Bioreactors CAR-T Cells CDMOs Cell Manufacturing and Cell Banking Cell Therapy for Diabetes Cytokine Release Syndrome Exosomes and Extracellular Vesicles Expedited Programs for Regenerative Medicine Genome Editing Genome-Edited Therapies for Blood Disorders GMP Hydrogels iPS Cells iPS-Derived Immune Cells iPS-Derived Neurons and Parkinson's Disease Lipid Nanoparticles (LNPs) Mesenchymal Stem Cells MHC and Universal Donor Cells mRNA Medicines Off-Target Effects and Safety Assessment Organoids and Spheroids QbD and CMC Regulatory Submissions and Real-World Data Transthyretin Amyloidosis (ATTR) Viral Vectors

Institution Profiles

8 organizations

AMED (Japan Agency for Medical Research and Development) California Institute for Regenerative Medicine (CIRM) Center for iPS Cell Research and Application (CiRA), Kyoto University European Medicines Agency (EMA) International Society for Stem Cell Research (ISSCR) Ministry of Health, Labour and Welfare (MHLW) PMDA (Pharmaceuticals and Medical Devices Agency) U.S. Food and Drug Administration (FDA)